Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 56, No 2 (2005)
Original paper
Submitted: 2013-02-15
Published online: 2006-03-24
View PDF (Polish) Download PDF file
Get Citation

Injection of methylprednisolone directly into the extraocular muscles of eyes with disturbed motility secondary to Graves’ opthalmopathy. Preliminary report

Andrzej Mikita, Zofia Mariak, Janusz Myśliwiec
Endokrynol Pol 2005;56(2):168-173.

open access

Vol 56, No 2 (2005)
Original Paper
Submitted: 2013-02-15
Published online: 2006-03-24

Abstract

Aim of the study was to estimate the efficacy of 6-α-methylprednisolone injection into involved extraocular muscles in eyes with motility disturbances caused by endocrine ophthalmopathy. Material and methods. For further evaluation we qualified 4 patients, 1 female and 3 males, aged: 60, 43, 42 and 64 years, with clinical activity score equal 4, with duration of Graves’ ophthalmopathy of mean 2.1 years (0.16-5.5). Included were patients with movement restrictions in vertical plane and echographic findings of isolated extraocular muscle involvement (inferior rectus). Each of the patients received 20 mg 6-α-methylprednisolone into the muscle belly of inferior rectus, in one case injection was done in both eyes.
Results. In all cases we were able to archive lessening of the intraocular pressure in secondary position, with slight improvement in ocular motility and bigger range of duction free of diplopia.
Conclusions. Visual function improvement found by the patients is the best evidence for application of 6-α-methylprednisolone into the extraocular muscles of patients with motility disturbances secondary to endocrine ophthalmopathy.

Abstract

Aim of the study was to estimate the efficacy of 6-α-methylprednisolone injection into involved extraocular muscles in eyes with motility disturbances caused by endocrine ophthalmopathy. Material and methods. For further evaluation we qualified 4 patients, 1 female and 3 males, aged: 60, 43, 42 and 64 years, with clinical activity score equal 4, with duration of Graves’ ophthalmopathy of mean 2.1 years (0.16-5.5). Included were patients with movement restrictions in vertical plane and echographic findings of isolated extraocular muscle involvement (inferior rectus). Each of the patients received 20 mg 6-α-methylprednisolone into the muscle belly of inferior rectus, in one case injection was done in both eyes.
Results. In all cases we were able to archive lessening of the intraocular pressure in secondary position, with slight improvement in ocular motility and bigger range of duction free of diplopia.
Conclusions. Visual function improvement found by the patients is the best evidence for application of 6-α-methylprednisolone into the extraocular muscles of patients with motility disturbances secondary to endocrine ophthalmopathy.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

Thyroid-Associated Ophthalmopathy; ocular motility disorders; diplopia; methylprednisolone

About this article
Title

Injection of methylprednisolone directly into the extraocular muscles of eyes with disturbed motility secondary to Graves’ opthalmopathy. Preliminary report

Journal

Endokrynologia Polska

Issue

Vol 56, No 2 (2005)

Article type

Original paper

Pages

168-173

Published online

2006-03-24

Page views

528

Article views/downloads

1218

Bibliographic record

Endokrynol Pol 2005;56(2):168-173.

Keywords

Thyroid-Associated Ophthalmopathy
ocular motility disorders
diplopia
methylprednisolone

Authors

Andrzej Mikita
Zofia Mariak
Janusz Myśliwiec

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl